LAB moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend. In 49 of 56 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on LAB as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for LAB just turned positive on November 04, 2026. Looking at past instances where LAB's MACD turned positive, the stock continued to rise in 41 of 54 cases over the following month. The odds of a continued upward trend are 76%.
Following a +10.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in 202 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 49 cases where LAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The 10-day moving average for LAB crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
LAB broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LAB entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (4.142). P/E Ratio (2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.300) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VNRX saw its Momentum Indicator move above the 0 level on November 13, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 73 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 77%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VNRX's RSI Indicator exited the oversold zone, 23 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
VNRX moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 46 cases where VNRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VNRX broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LAB | VNRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 47 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 45 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 50 | 100 | |
PRICE GROWTH RATING 1..100 | 73 | 90 | |
P/E GROWTH RATING 1..100 | 77 | 6 | |
SEASONALITY SCORE 1..100 | 50 | 25 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VNRX's Valuation (45) in the Medical Or Nursing Services industry is in the same range as LAB (51) in the Medical Specialties industry. This means that VNRX’s stock grew similarly to LAB’s over the last 12 months.
VNRX's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as LAB (100) in the Medical Specialties industry. This means that VNRX’s stock grew similarly to LAB’s over the last 12 months.
LAB's SMR Rating (50) in the Medical Specialties industry is somewhat better than the same rating for VNRX (100) in the Medical Or Nursing Services industry. This means that LAB’s stock grew somewhat faster than VNRX’s over the last 12 months.
LAB's Price Growth Rating (73) in the Medical Specialties industry is in the same range as VNRX (90) in the Medical Or Nursing Services industry. This means that LAB’s stock grew similarly to VNRX’s over the last 12 months.
VNRX's P/E Growth Rating (6) in the Medical Or Nursing Services industry is significantly better than the same rating for LAB (77) in the Medical Specialties industry. This means that VNRX’s stock grew significantly faster than LAB’s over the last 12 months.
| LAB | VNRX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 76% | N/A |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 73% |
| Advances ODDS (%) | 2 days ago 83% | 6 days ago 73% |
| Declines ODDS (%) | 4 days ago 87% | 25 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LAB’s FA Score shows that 0 FA rating(s) are green while VNRX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LAB’s TA Score shows that 4 TA indicator(s) are bullish while VNRX’s TA Score has 4 bullish TA indicator(s).
LAB (@Medical/Nursing Services) experienced а +11.23% price change this week, while VNRX (@Medical/Nursing Services) price change was +17.41% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.37%. For the same industry, the average monthly price growth was -4.49%, and the average quarterly price growth was -5.80%.
LAB is expected to report earnings on Nov 17, 2026.
VNRX is expected to report earnings on Mar 30, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, LAB has been loosely correlated with RVTY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LAB jumps, then RVTY could also see price increases.
| Ticker / NAME | Correlation To LAB | 1D Price Change % | ||
|---|---|---|---|---|
| LAB | 100% | +8.60% | ||
| RVTY - LAB | 44% Loosely correlated | -1.67% | ||
| ILMN - LAB | 41% Loosely correlated | -1.21% | ||
| RGEN - LAB | 38% Loosely correlated | +0.76% | ||
| A - LAB | 37% Loosely correlated | +0.55% | ||
| QGEN - LAB | 37% Loosely correlated | -0.42% | ||
More | ||||
A.I.dvisor tells us that VNRX and LAB have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VNRX and LAB's prices will move in lockstep.
| Ticker / NAME | Correlation To VNRX | 1D Price Change % | ||
|---|---|---|---|---|
| VNRX | 100% | +24.66% | ||
| LAB - VNRX | 27% Poorly correlated | +8.60% | ||
| STRRP - VNRX | 27% Poorly correlated | N/A | ||
| SSII - VNRX | 26% Poorly correlated | +25.76% | ||
| BMRA - VNRX | 26% Poorly correlated | +3.03% | ||
| IMDX - VNRX | 24% Poorly correlated | -7.36% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GUSH | 42.13 | 0.87 | +2.11% |
| Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X ETF (GUSH) | |||
| FDL | 54.17 | 0.54 | +1.01% |
| First Trust Morningstar Dividend Leaders Index Fund (FDL) | |||
| IAUI | 45.04 | 0.11 | +0.24% |
| NEOS Gold High Income ETF (IAUI) | |||
| IVSI | 28.99 | N/A | N/A |
| Applied Finance IVS International Large ETF | |||
| AGQI | 18.02 | N/A | -0.02% |
| First Trust Active Global Quality Income ETF (AGQI) | |||